Annexin Pharmaceuticals AB (publ) (OM: ANNX)
Health Care · Pharmaceuticals · SE
Skr13.20
+5.18% today · -51.1% 1Y
Annexin Pharmaceuticals AB (publ) (OM: ANNX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $9.84M and employs 4 people.
Over the last twelve months the share price has lost 51.1%, trading between 11.05 and 29.80.
Tweenvest scores Annexin Pharmaceuticals AB (publ) across four factors: quality 26/100. Its strongest factor is quality.
ANNX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.84M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.30
- 52-week high
- Skr29.80
- 52-week low
- Skr11.05
- Avg volume (3M)
- —
- Shares outstanding
- 7.06M
- Employees
- 4
- Next earnings
- —
About Annexin Pharmaceuticals AB (publ)
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.
- ISIN
- SE0025159387
- Founded
- 2014
- Listed since
- Apr 19, 2017
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,199.54 | -2.77% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.17 | -1.09% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.68 | -1.77% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.46 | -0.40% |
Figures last refreshed Aug 18, 2026.